Introduction {#s1}
============

Non-coding RNA (ncRNA) is a kind of RNA molecule that is not translated into protein ([@B2]; [@B46]). In decades past, lncRNA was considered as transcriptional noise and few people studied it. Nowadays, accumulating evidence has proved the key regulatory role of lncRNAs in many significant biological processes ([@B18]). For example, some mutated and dysfunctional lncRNAs were implicated in a lot of human diseases such as renal cancer ([@B34]; [@B48]), breast cancer ([@B1]; [@B23]), hepatocellular cancer ([@B3]; [@B36]), prostate cancer ([@B15]; [@B43]), lung cancer ([@B27]; [@B53]), colon cancer ([@B37]), leukemia ([@B3])and cardiovascular diseases ([@B14]). There are many well-known lncRNA-related biological databases such as NRED ([@B16]), NONCODE ([@B31]; [@B47]; [@B55]), LncRNADisease ([@B5]), Lnc2Cancer ([@B35]) and lncRNAdb ([@B39]), including the information about lncRNA and little lncRNA--disease associations.

Recently, exploiting potential lncRNA--disease associations have become a growing significant research area. Many associations between lncRNA and human diseases have been identified by medical experiments, but which is costly and time-consuming. Predicting potential associations by the mathematical method and computational inference for experimental verification is a quite certain well-selected alternative ([@B8]; [@B10]).

[@B4] presented the Laplacian Regularized Least Squares for LncRNA--Disease Association (LRLSLDA), which is a semi-supervised learning framework to identify potential associations by integrating known associations and lncRNA expression profiles. [@B32] put forward a computational model to predict potential lncRNA--disease associations by integrating many types of data such as gene expression profiles, human lncRNA expression profiles, and human disease-associated gene data. [@B30] presented a prediction method based on genome location information to discover potential vascular disease-related lncRNAs. [@B41] established a lncRNA functional similarity network and used the random walk model to predict potential lncRNA--disease associations. However, this method cannot be applied to the lncRNAs without any known associated diseases. [@B52] also proposed a network-based method to identify lncRNA--disease associations. And Yang's method had a great performance to predict lncRNA--disease associations but it did not take into account various similarities. [@B11] constructed a Katz measure model (KATZLDA) to predict lncRNAs associated with diseases, especially isolated disease-related lncRNAs. However, the method relies excessively on a network topology structure. [@B38] constructed a lncRNA--disease bipartite network to infer potential lncRNA--disease associations by integrating two similarity calculation methods for lncRNAs and diseases. [@B20] developed a dual sparse collaborative matrix factorization method based on gaussian kernel function (DSCMF) to predict novel lncRNA--disease associations. They considered the sparsity of lncRNA--disease association and used the L2,1-norm to ensure its sparsity in optimization.

In this paper, we developed an improved diffusion model for predicting lncRNA--disease associations (IDLDA) based on the hypothesis that phenotypically similar diseases are often associated with functionally similar lncRNAs and *vice versa*. IDLDA achieved reliable predictions with global and local cross-validations and it obtained higher AUROC than some previously proposed methods. Our results showed that the predicted top 10 lncRNAs in both databases were confirmed by databases and literature, and there were only 2, 2, and 1 lncRNAs which ranked top 50 by IDLDA in both databases that were not confirmed. All these results demonstrated the effectiveness and value of IDLDA in identifying potential lncRNA--disease associations. Data and code are freely available for research purposes only, you can email the author for it.

Materials and Methods {#s2}
=====================

Data Collection and Pre-Processing {#s2_1}
----------------------------------

LncRNADisease ([@B5]) and Lnc2Cancer ([@B35]) are two well-known databases that we can apply to extract known lncRNA--disease associations. We got 687 experimentally verified lncRNA-disease associations ([**Supplementary Tables 1**](#SM1){ref-type="supplementary-material"} and [**3**](#SM3){ref-type="supplementary-material"}) including 372 lncRNAs and 246 diseases in the LncRNADisease, and 1,102 experimentally verified lncRNA-disease associations ([**Supplementary Tables 2**](#SM2){ref-type="supplementary-material"} and [**4**](#SM4){ref-type="supplementary-material"}) including 667 lncRNAs and 97 cancers in the Lnc2Cancer. These datasets were utilized as not only the gold standard datasets in the cross-validation but also the training datasets in novel lncRNA--disease association prediction. In addition, we also combined the data from the two datasets to make a complete training data set for validation which named combined dataset. There are 1669 experimentally verified lncRNA--disease associations including 944 lncRNAs and 295 diseases. This dataset ([**Supplementary material Data Sheet 1**](#SM6){ref-type="supplementary-material"}) can better illustrate the credibility of the model. To the author's knowledge, this is the first article to combine the data of these two databases for model validation.

We constructed lncRNA--disease associations as a bipartite graph *G*(*V*,*E*) as follows. *V*=*L*∪^​^ *D* is the vertex set, where *L* is the lncRNA set { *l* ~1~,*l* ~2~,...,*l* *~Nl~* }, *D* is the disease set { *d* ~1~,*d* ~2~,...,*d* *~Nd~* }, and denote the edge set *E*={ *e* *~ij~*:*d* *~i~*∈*D*,*l* *~j~*∈*L* }. *N* *~d~* and *N* *~l~* represent the number of diseases and the number of lncRNAs, respectively. Here, the lncRNA--disease association can be represented by an adjacency matrix *A*={*a* *~ij~*}*~Nd~* ~×~ *~Nl~*, where *a* *~ij~*=1 if disease *d* *~i~* and lncRNA *l* *~j~* have experimentally validated relation in the databases, while the unknown associations are set to 0 indicating that they will be ranked.

For every disease term *d* *~j~* in the MeSH database, we constructed a directed acyclic graph *DAG*(*d* *~j~*) based on the MeSH descriptors of Category C downloaded from the National Library of Medicine. For example, [**Figure 1**](#f1){ref-type="fig"} represents the DAG of lung neoplasms. All vertices in the DAG are connected by a direct edge from a more general term, we call it parent, to a more specific term, and we call it child ([@B6]). Here, *V*(*DAG*(*d* *~j~*)) indicated the vertex set including vertex *d* *~j~* and its ancestor vertices, and *E*(*DAG*(*d* *~j~*)) was the edge set of corresponding direct links from a parent vertex to a child vertex, which represented the relationship between different diseases.

![The disease DAG of lung neoplasms.](fgene-10-01259-g001){#f1}

Ensemble Similarity {#s2_2}
-------------------

### Disease Ensemble Similarity {#s2_2_1}

For a given disease *d* *~j~*, in the *DAG*(*d* *~j~*), the contribution of each disease semantic term *C* *~dj~*(*d* *~i~*) of disease *d* *~i~* was defined as follows ([@B45]):
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where Δ was a decay factor of semantic contribution, which should be between 0 and 1. According to some previous studies ([@B45]; [@B6]; [@B11]), this value was 0.5 here. Accordingly, the contribution to the semantic value of disease *d* *~j~* itself was defined as 1. Meanwhile, the contribution of its ancestor disease should be multiplied by Δ.

According to this way to measure disease semantic similarity, we thought that two diseases *d* *~i~* and *d* *~j~* which had a larger *DAG*(*d* *~i~*) ∩^​^ *DAG*(*d* *~j~*) should have a higher semantic similarity. Thus, the semantic score of disease *d* *~j~* was acquired by adding up all the contributions from ancestor diseases and disease *d* *~j~* itself. Define the semantic score (*C*) of disease *d* *~j~* as follows:
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Thus, disease semantic similarity (*SS*) between disease *d* *~i~* and disease *d* *~j~* can be written as ([@B9]):
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Based on the basic assumption that two lncRNAs with more functional similarity prefer to be more related to similar diseases and *vice versa* ([@B33]), we could obtain disease similarity by the topologic information of the known lncRNA--disease association network. Accordingly, we introduced the Gaussian interaction profile kernel for calculating the similarity between diseases as a part of the disease similarity ([@B44]; [@B4]). Then we utilized the following equation to obtain disease Gaussian kernel similarity (*KD*) between disease *d* *~i~* and disease *d* *~j~*.
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where *IP*(*d* *~i~*) was the *i*-th column of matrix *A*. The parameter *γ* *~d~* was a parameter for adjusting the bandwidth of the kernel, which should be updated by using a new bandwidth parameter $\gamma_{d}^{’}$ divided by the average value of the associations with lncRNAs for all diseases. According to the previous study ([@B13]; [@B42]), $\gamma_{d}^{’}$ was set to 1 to control thekernel bandwidth.

Thus, *γ* *~d~* could be defined as follows:
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Define the disease ensemble similarity (*DS*) between disease *d* *~i~* and disease *d* *~j~* as follows:
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### LncRNA Ensemble Similarity {#s2_2_2}

For a disease *d* *~i~* and a group of diseases *D*, their similarity score *S* between them was defined as ([@B6]):
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Let *D*(*l* *~i~*) and *D*(*l* *~j~*) be the set of diseases related to lncRNA *l* *~i~* and lncRNA *l* *~j~*, respectively. Define similarity score *S* between *D*(*l* *~i~*) and *D*(*l* *~j~*) as follows:
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Usually, most of researchers believe that lncRNAs with similar functions are more likely related to similar diseases and *vice versa* ([@B51]; [@B4]; [@B32]; [@B41]; [@B52]; [@B6]; [@B11]; [@B21]). Therefore, the functional similarity between lncRNA *l* *~i~* and lncRNA *l* *~j~* was calculated as follows:
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where \| *D*(*l* *~i~*) \| and \| *D*(*l* *~j~*) \| were the numbers of diseases associated with lncRNA *l* *~i~* and lncRNA *l* *~j~*, respectively.

Similarly, the Gaussian kernel similarity between lncRNA *l* *~i~* and lncRNA *l* *~j~* was defined as follows ([@B44]; [@B4]):
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where $\gamma_{l}^{’}$ = 1 ([@B13]; [@B42]).

Define the lncRNA ensemble similarity (*LS*) between lncRNA *l* *~i~* and lncRNA *l* *~j~* as follows:
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Ensemble Associations {#s2_3}
---------------------

On the basis of the ensemble similarity matrix *DS* and *LS*, we could obtain two ensemble associations *DA*={ *DA* *~ij~* }*~Nd~* ~×~ *~Nl~* and *LA*={ *LA* *~ij~* }*~Nd~* ~×~ *~Nl~*. *DA* *~ij~* and *LA* *~ij~* can be written as:
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An Improved Diffusion Model on the Network {#s2_4}
------------------------------------------

We applied an improved diffusion model to calculate the information transmitted in the bipartite graph, which was quantified to solve the correlation between lncRNAs and diseases.

First of all, we selected one disease *D* *~u~* as seed, so the initial resources were located on each lncRNA, which associated with disease *D* *~u~*. Based on the hypothesis that lncRNAs with similar functions are usually related to similar diseases and *vice versa*. All the initial resources in *L* flowed to *D* by *LA* and *DA*. Thus, the comprehensive index (resources) of the *d* *~j~* vertex was shown as follows:
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Each disease scattered the received resources to its associated lncRNAs, the resources located on the *d* *~j~* vertex returned back to *L* by *LA* and *DA*. Then the final comprehensive index (resources) of the *l* *~i~* vertex as shown below:
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Here the parameters α, β were used to balance the contribution between *LA* and *DA*. Therefore, for a given disease *D* *~u~*, we could obtain the comprehensive index IDLDA-score of every lncRNA. Accordingly, we got the predicted ranks of all lncRNAs for every disease. This predicted result can be represented by a rank matrix *R*={*r* *~ij~*}*~Nd~* ~×~ *~Nl~*, where *r* *~ij~* indicated the relevance score between disease *d* *~i~* and lncRNA *l* *~j~*. The larger the value of *r* *~ij~*, the more likely disease *d* *~i~* and lncRNA *l* *~j~* are to be related. Thus, IDLDA can predict not only new disease-related lncRNAs but new lncRNA-related diseases. The flow chart of IDLDA is shown in [**Figure 2**](#f2){ref-type="fig"}.

![Flowchart of IDLDA. N~d~ and N~l~ represent the number of diseases and the number of lncRNAs, respectively.](fgene-10-01259-g002){#f2}

Results {#s3}
=======

In this section, we first analyzed some properties of the lncRNA--disease association network. Next, we used global and local cross-validations and performed enrichment analysis to evaluate the performance of IDLDA. Then, we conducted case studies to verify the efficiency of IDLDA in discovering some potential disease-related lncRNAs.

Properties of the lncRNA--Disease Association Network {#s3_1}
-----------------------------------------------------

We analyzed the lncRNA--disease association network's characteristics to obtain a whole view of it ([**Table 1**](#T1){ref-type="table"}). Among them, density denotes the number of edges divided by the number of possible edges. As we can see from [**Table 1**](#T1){ref-type="table"}, there are very few associations available, so it is very important to predict potential associations.

###### 

Global characteristics of the lncRNA--disease association.

  ------------------ -------------------- --------------------- ------------------------- -------------
                     **No. of lncRNAs**   **No. of Diseases**   **No. of Associations**   **Density**
  LncRNADisease      372                  246                   687                       0.0075
  Lnc2Cancer         667                  97                    1,102                     0.0170
  Combined dataset   944                  295                   1,669                     0.0060
  ------------------ -------------------- --------------------- ------------------------- -------------

Cross-Validation Tests {#s3_2}
----------------------

A receiver operating characteristic (ROC) curve is a graphical plot that shows the diagnostic ability of the binary classifier system because its recognition thresholds are different ([@B19]). AUROC (Area Under Receiver Operating Characteristic Curve) is the area under the ROC curve with a value between 0 and 1. AUROC can intuitively evaluate the quality of classifier, the larger the value, the better. The similarities between diseases and lncRNAs rely on known associations. Therefore, the disease ensemble similarity and lncRNA ensemble similarity should be recalculated in each repetition of the experiment. The IDLDA method had two parameters, i.e. α and β. Here, when the values of α and β took 0, 0.1, 0.2, ...,1 the values in the leave-one-out cross-validation (LOOCV), the AUROC were calculated. The highest AUROC value was 0.9513 (α=0.3, β=0.5) in the combined dataset. As a result, the parameters (α, β) in the combined dataset was (0.3, 0.5).

Our model could predict not only new lncRNAs but also new diseases. Here, we adopt three cross-validations to evaluate the prediction accuracy of the model from global and local perspectives. The first cross-validation is LOOCV, some elements in the matrix A were randomly selected as the training set and the remaining elements as the test set; the second cross-validation is CVr, selected some rows of the matrix A randomly as the training set and the remaining data as the test set; the third cross-validation is CVc, selected some columns of the matrix A randomly as a training set and the remaining data as a test set.

Among the three cross-validations, LOOCV was global cross-validation, which could test the prediction accuracy of the model on the original data set. For LOOCV, each known lncRNA--disease association was taken in turn as a testing sample and the remaining associations were used as training samples. And the baseline indicated random performance. In order to ensure the consistency of input data, the similarities of diseases and lncRNAs in other methods is consistent with the similarity of the IDLDA, which can better compare the predictive ability of the model itself. The AUROC of the combined dataset was 0.9513. We demonstrated that our approach significantly outperforms great performance ([**Supplementary Table 5**](#SM5){ref-type="supplementary-material"}). CVr and CVc were local cross-validations, which could test the prediction accuracy of the model for newly added diseases and lncRNAs respectively. The results of CVr ([**Figure 3**](#f3){ref-type="fig"}, Left) and CVc ([**Figure 3**](#f3){ref-type="fig"}, Right) showed that IDLDA had great performance in predicting novel lncRNA-related diseases and disease-related lncRNAs.

![The ROC curves of the different methods with local cross-validation by row (Left) and by column (Right).](fgene-10-01259-g003){#f3}

Enrichment Analysis {#s3_3}
-------------------

To check whether the lncRNAs with high IDLDA-score were more likely to be disease-related, all candidate lncRNA--disease pairs in two databases were ranked by IDLDA and binned into groups of *x*. Here, we took *x* as 1000 for the data in the LncRNADisease and Lnc2Cancer, and as 10000 for the data in the combined dataset. A fold enrichment score was defined as $\left( \frac{m}{x} \right)/\left( \frac{M}{N} \right)$ ([@B26]), where *m* was the number of distinct experimentally verified associations within one certain bin of *x*, *M* was the number of all distinct experimentally verified lncRNA--disease associations, and *N* was the number of all possible lncRNA--disease associations. For an lncRNA--disease pair, if its fold enrichment score was high for certain bin, it represented this pair was more likely to be related. As shown in [**Figure 4**](#f4){ref-type="fig"}, lncRNAs with high IDLDA-score were more likely to be disease-related in three datasets.

![Enrichment analysis in three datasets.](fgene-10-01259-g004){#f4}

Case Studies {#s3_4}
------------

Case studies were implemented to examine the capability of IDLDA in discovering potential lncRNA--disease associations. For some special diseases, we ranked those candidate lncRNAs based on their corresponding IDLDA-scores. Case studies included three common human diseases (colon cancer, gastric cancer, and breast cancer). Prediction results were verified based on not only the recent updates in the Lnc2Cancer and LncRNADisease but recently published experimental literature. Then we observed the number of the verified lncRNAs in the top 10 and 50 predictions in both databases, all the ranking results have been listed in [**Tables 2**](#T2){ref-type="table"}--[**4**](#T4){ref-type="table"}.

###### 

Case study of colon cancer.

  ------------ --------------------- ----------------------- --------------------------
  **lncRNA**   **Evidence (PMID)**   **Rank (Lnc2Cancer)**   **Rank (LncRNADisease)**
  HOTAIR       24667321              1                       4
  MALAT1       22996375              2                       3
  MEG3         14602737              3                       5
  H19          21874233              4                       1
  ANRIL        23416462              5                       14
  GAS5         28722800              6                       7
  UCA1         26885155              7                       10
  PVT1         29552759              8                       6
  NEAT1        26552600              11                      33
  SPRY4-IT1    27621655              16                      36
  XIST         29679755              23                      8
  PTENP1       Unconfirmed           36                      11
  ------------ --------------------- ----------------------- --------------------------

###### 

Case study of breast cancer.

  ------------- --------------------- ----------------------- --------------------------
  **lncRNA**    **Evidence (PMID)**   **Rank (Lnc2Cancer)**   **Rank (LncRNADisease)**
  HOTAIR        24721780              1                       4
  MALAT1        22492512              2                       3
  H19           16707459              3                       1
  MEG3          14602737              4                       6
  ANRIL         17440112              5                       13
  UCA1          26439035              6                       10
  GAS5          29655698              7                       7
  TUG1          28053623              8                       49
  PVT1          17908964              9                       5
  NEAT1         2541770               10                      18
  XIST          24141629              15                      9
  HIF1A-AS1     Unconfirmed           16                      43
  LincRNA-p21   26656491              18                      42
  SPRY4-IT1     25742952              20                      46
  LSINCT5       21532345              26                      50
  PANDAR        26927017              27                      20
  KCNQ1OT1      26323944              37                      38
  PCAT1         28989584              39                      17
  DLEU2         Unconfirmed           45                      39
  PTENP1        29085464              50                      12
  ------------- --------------------- ----------------------- --------------------------

###### 

Case study of gastric cancer.

  ------------- --------------------- ----------------------- --------------------------
  **lncRNA**    **Evidence (PMID)**   **Rank (Lnc2Cancer)**   **Rank (LncRNADisease)**
  HOTAIR        29683069              1                       4
  MALAT1        29162158              2                       3
  H19           29687854              3                       1
  MEG3          28975980              4                       5
  ANRIL         24810364              5                       13
  UCA1          29723509              6                       11
  GAS5          27827524              7                       7
  PVT1          26925791              8                       6
  NEAT1         27095450              9                       33
  XIST          29053187              14                      9
  LincRNA-p21   28969031              20                      40
  LSINCT5       25694351              21                      41
  PANDAR        29719612              24                      17
  KCNQ1OT1      Unconfirmed           26                      36
  SRA1          Unconfirmed           49                      30
  ------------- --------------------- ----------------------- --------------------------

Colon cancer is one of the most common malignant tumors in the world ([@B49]), killing almost seven hundred thousand people every year ([@B21]), even the disease-specific mortality rate is close to 33% in the developed countries ([@B24]). In 2018, there are 97220 estimated new cases and 50,630 estimated deaths from Colon Neoplasms in U.S. ([@B40]). Some associations between colon cancer and lncRNAs have been discovered by biological experiments ([@B6]), IDLDA can also predict more colon cancer-related lncRNAs. Consequently, all potentially related lncRNAs which ranked top 10 in both databases had been validated by databases and recent experimental literature. Meanwhile, only PTENP1 which ranked top 50 in both databases was not verified. Some research showed that PTENP1 pseudogene may act as "decoy" by protecting PTEN mRNA from binding to common miRNA and allowing expression of the tumor suppressor protein ([@B29]). This indicated that PTENP1 was associated with cancer.

Breast cancer is the second leading cause of cancer deaths in women, accounting for 22% of all cancer deaths in women ([@B17]; [@B28]). Some researchers announced that a number of lncRNAs are associated with the formation of breast cancer ([@B34]; [@B48]). In this paper, we used IDLDA to discover the potential breast cancer-related lncRNAs. From [**Table 3**](#T3){ref-type="table"}, we could know that all the potential related lncRNAs which ranked top 40 in both databases had been validated. For example, HOTAIR was ranked first in Lnc2Cancer, recent research had confirmed that HOTAIR was strongly expressed in numerous cancers like breast cancer, colorectal cancer, and lung cancer ([@B23]; [@B29]; [@B25]). Only HIF1A-AS1 and DLEU2 in both databases had not been validated by the same resources.

Gastric cancer is the second major reason for cancer-related death in the world ([@B22]). A myriad of studies has proved that lncRNAs have played crucial roles in the development of gastric cancer ([@B54]). It is clear that the associations between breast cancer and HOTAIR, MALAT1, H19, MEG3, ANRIL, UCA1, GAS5, PVT1, NEAT1, XIST, LincRNA-p21, LSINCT5, PANDAR were validated by databases and related literature from [**Table 4**](#T4){ref-type="table"}. Only KCNQ1OT1 and SRA1 were not confirmed. But there is a potential relationship between SRA1 and breast cancer ([@B50]), SRA RNA expression is altered during breast tumorigenesis. The semantic similarity between gastric cancer and breast cancer is very large, perhaps future research could explain the relationship between SRA1 and gastric cancer.

Discussion {#s4}
==========

According to previous literature, lncRNAs are associated with a mass of diseases. With the emergence of many biological data about lncRNA, it is urgent to design a powerful and effective computing method to predict the underlying disease-related lncRNAs. In this paper, disease semantic similarity, lncRNA functional similarity, disease/lncRNA Gaussian kernel similarity, and lncRNA--disease associations were integrated on a large scale. We developed a computational model named IDLDA, which based on the diffusion model to predict potential lncRNA--disease associations. IDLDA achieved higher AUROC than other methods in the combined dataset. Meanwhile, local cross-validation, enrichment analysis could also show the reliability of the model. Moreover, case studies of colon cancer, breast cancer, and gastric cancer were also implemented, all lncRNAs which ranked top 10 in both databases were verified, only 2, 2, and 1 lncRNAs which ranked top 50 in both databases were not confirmed by databases and related literature. What is more, the results of local cross-validation showed IDLDA can predict not only new disease-related lncRNAs but new lncRNA-related diseases.

Here are the reasons why IDLDA performs better than some aforementioned methods. Firstly, the lncRNA ensemble similarity and disease ensemble similarity can make full use of the information about known lncRNA--disease associations by integrating lncRNA functional similarity, disease semantic similarity, and the Gaussian kernel similarity. Secondly, both disease ensemble similarity and lncRNA ensemble similarity are used in the diffusion process, IDLDA could predict not only new lncRNAs but also new diseases, overcoming some limitations of previous methods. Thirdly, IDLDA as a semi-supervised method is superior to the supervised methods when the data is incomplete. In particular, semi-supervised method could be implemented without any negative lncRNA--disease associations, which are closer to reality. In short, IDLDA will be an important and powerful bioinformatics tool in biomedical research of the lncRNA--disease association prediction, and even disease treatment.

Although IDLDA is effective, this work has several limitations. Firstly, IDLDA contains two parameters, and finding suitable parameters for different datasets is a challenging task. Additionally, some specific lncRNAs are not associated with certain diseases. If this kind of data can be added to the model in the future, it will certainly be helpful to improve the predictive ability. Successfully established models in the other computational fields would inspire the development of lncRNA--disease association prediction. Perhaps we can improve the predictive performance of IDLDA by integrating more information, such as lncRNA--miRNA information ([@B12]) and disease--drug information ([@B7]).
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